Athenex plans to apply $28 million of the IPO proceeds to this trial. Athenex is already planning to seek approval of its oral paclitaxel overseas. The company says it expects to submit filings for approval in New Zealand and Taiwan within the next 18 months.
( read original story …)
Search your Hotel